絞り込み

18454

広告

Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III clinical trials.

著者 Gu ZC , Kong LC , Yang SF , Wei AH , Wang N , Ding Z , Zhang C , Liu XY , Zheng YL , Lin HW
Cardiovasc Diagn Ther.2019 Oct ; 9(5):410-419.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (12view , 0users)
Atrial fibrillation (AF) is quite prevalent in patient with chronic kidney disease (CKD). This study mainly investigated the net clinical benefit (NCB) property of non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with AF and CKD by a pooled-analysis.
PMID: 31737513 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード